Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA -- more

Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis -- more

ExonHit Appoints a New Management Board -- more

Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update -- more

Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug -- more

BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing -- more

February 29, 2008: Santhera Reports Financial Results and Significant Operational Progress for 2007 -- more

Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer -- more

Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance -- more

Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement -- more

Mitralign Successfully Completes First Human Case -- more

AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma -- more

Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes —CTA Acceptance in the Netherlands Triggers Milestone Payment to Eisai -- more

Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA -- more

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors -- more

ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule -- more

Critical Therapeutics Receives $5.0 Million Milestone Payment from DEY for Commercial Launch of ZYFLO CR -- more

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project -- more

Coherex Medical Hires Top Medical Industry Veteran to Fill Global Market Development Seat -- more

Mitralign Announces Closing of Series C Financing -- more

Health Canada Accepts Santhera's Submission for Marketing Authorization of SNT-MC17 in Friedreich's Ataxia -- more

Dicerna, Startup Based on RNAi Biology, Licenses IP from City of Hope and Closes $13 Million Series A Financing -- more

Santhera Showcases Potential and Progress of its Clinical Development Pipeline -- more

Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease --

more

ExonHit Completes a Prototype to Detect Alzheimer’s Disease from Blood -- more

Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease -- more

Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease -- more

AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer -- more

Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies -- more

Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy -- more

Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer -- more

Santhera's CSO Thomas Meier Receives BioValley Award for Scientific and Entrepreneurial Merits -- more

Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study -- more

Critical Therapeutics Announces Enrollment in Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD -- more

Critical Therapeutics Announces the Issuance of Four New Patents for Its Alpha-7 and HMGB1 Preclincial Programs -- more

Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia -- more

Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol Fumarate) Inhalation Solution -- more

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia -- more

Coherex Medical, Inc., a privately held medical device company,today announced it has successfully completed the first human cases of its Coherex FlatStent(TM) PFO Closure System -- more

AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates -- more

OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration -- more

Critical Therapeutics Initiates Phase I Clinical Trial of the R(+) Isomer of Zileuton -- more

Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design -- more

Ceres Raises $75 Million in Late-Stage Financing -- more

BrainCells Inc., Taisho Pharmaceutical Co., Ltd. Sign Licensing Agreement for Novel CNS Program -- more

Critical Therapeutics and Dey Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets -- more

Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development -- more

Elixir Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering -- more

Santhera to Seek Canadian Market Approval for SNT-MC17 in Friedreich's Ataxia -- more

Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis -- more

Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells -- more

Critical Therapeutics Announces Publication of Results from Two Asthma Studies -- more

Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis -- more

Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia -- more

Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 -- more

FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry -- more

Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials -- more

Concentric Medical, Inc. Files Registration Statement for Proposed Initial Public Offering -- more

Santhera's 2007 Interim Results Reflect Increased Investment in Advanced Development Pipeline -- more

European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera -- more

BioProcessors Raises $10 Million -- more

Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy -- more

Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases -- more

Intechra Adds National Logistics Network, Two Acquisitions -- more

Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial -- more

Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled -- more

Santhera Licenses Omigapil for Treatment of Rare Neuromuscular Diseases -- more

Critical Therapeutics' Zileuton Provides Additional Asthma Control When Combined with Inhaled Corticosteroids -- more

ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia -- more

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting -- more

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes -- more

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -- more

AVEO Pharmaceuticals' CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur of the Year® Award -- more

Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia -- more

Critical Therapeutics Announces the Publication of Data for ZYFLO CR(TM) (Zileuton) Extended-Release Tablets in the Journal of Asthma -- more

ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis -- more

Agilent Technologies Adds Strength to Its Life Science Business with Acquisition of Stratagene -- more

Dynogen Reports Positive Results in Phase 1B GERD Study -- more

Cardiome and Astellas Announce Positive Results from ACT 2 Trial -- more

Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer -- more

Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML -- more

FDA Approves Critical Therapeutics' Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for Asthma -- more

Intechra Secures Additional $30 Million in Equity Capital -- more

Solstice Neurosciences, Inc. Announces Commercialization Agreement -- more

Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD -- more

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex -- more

AVEO Pharmaceuticals Closes $53 Million in Series D Funding -- more

Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma -- more

CircuLite Closes an Additional $5M in Series B Private Placement Funding -- more

Xanthus Acquires from Johns Hopkins University Exclusive License to Patent Estate Covering FLT3 Pathway as a Target for Treating Autoimmune Diseases -- more

Stratagene Signs Definitive Agreement to Be Acquired by Agilent Technologies -- more

Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial -- more

AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody -- more

ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering -- more

Radius Raises $57.5 Million in Second Private Financing Round -- more

Nfocus Neuromedical Inc. Raises over $20 Million in Series B Financing -- more

Santhera Announces Appointment of Cesare Mondadori as Head of Research -- more

BrainCells and Lundbeck Form CNS Drug Research Collaboration -- more

Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors -- more

Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis -- more

ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial -- more

ExonHit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease -- more

Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing -- more

Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products -- more

Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease -- more

Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug Discovery, Development and Commercialization Collaboration -- more

Lilly Announces Acquisition of Hypnion -- more

FlowMedica: Targeted Renal Therapy for Patients at Risk for Contrast-Induced Nephropathy -- more

Asterand Offers Researchers Internet Access to RNA to Speed Drug Discovery -- more

Santhera Reports Successful 2006 -- more

Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board -- more

Cyberkinetics Files to Market Andara(TM) OFS(TM) Therapy for Acute Spinal Cord Injury under Humanitarian Device Exemption -- more

Critical Therapeutics Announces Beckman Coulter Exercises Option to Continue HMGB1 Diagnostic Development -- more

Elixir Pharmaceuticals and Siena Biotech S.p.A. Enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease -- more

Dynogen Reports Positive Results in Phase 2 IBS-c Study -- more

Santhera Intends Early Filing in Europe for SNT-MC17/idebenone in Friedreich's Ataxia -- more

Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US -- more

Critical Therapeutics Licenses Rights for Vagus Nerve Stimulation Device to Innovative Metabolics -- more

Claros Diagnostics Secures $7.8 Million Series A Financing to Develop Handheld Point-of-care Diagnostics Platform -- more

Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes -- more

Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis -- more

Solexa Genome Analysis System Achieves 1G Performance Milestone -- more

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin -- more

Cohesive Technologies Inc.: Thermo Fisher Scientific Acquires Provider of Sample Extraction and Liquid Chromatography -- more

Critical Therapeutics Announces NIH-Sponsored Study to Investigate the Efficacy Of ZYFLO(R) In Patients with Acute Exacerbations Of COPD -- more

Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors -- more

Xanthus Presents Preclinical Data Demonstrating Potent Symadex Activity in Leukemia Cells -- more

Memory Pharmaceuticals Announces Release of Clinical Hold on MEM 3454 -- more

Xanthus Completes Enrollment of Phase 2 Trial of Xanafide for the Treatment of Secondary AML -- more

Astex Therapeutics Appoints John Aston Chief Financial Officer -- more

Xanthus Secures $25 Million to Advance Development of Its Pipeline -- more

Santhera and Biozentrum Basel participate in the pan-European TREAT-NMD initiative to advance the treatment of rare neuro-muscular diseases -- more

ImpactRx, Inc. Names Altus President and Chief Executive Officer -- more

Memory Pharmaceuticals Completes Enrollment for MEM 1003 Bipolar Trial -- more

Memory Pharmaceuticals Earns Milestone Payment for Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

The Leukemia & Lymphoma Society and Ensemble Discovery Corp. Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers -- more

NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia -- more

Solstice Neurosciences Raises $85 Million in Private Financing -- more

Mitralign Shines at TCT 2006; Performs Live Case & Reveals Clinical Strategy -- more

Pathway Medical Closes $25 Million in Funding -- more

Critical Therapeutics Announces Closing of $20.0 Million Registered Direct Offering -- more

Memory Pharmaceuticals to Receive $2 Million Milestone from Roche Related to MEM 3454 -- more

Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. -- more

Critical Therapeutics Outlines New Business Strategy Focusing on Controlled-Release and Intravenous Formulations of Zileuton -- more

Critical Therapeutics to Sell 7.5 Million Shares of Registered Common Stock and Warrants to Purchase 3.7 Million Shares of Common Stock -- more

VaxInnate Secures $40 Million Series C Financing -- more

Asterand Isolates New Approach to Arthritis Research -- more

Alantos Pharmaceuticals and Servier Form Collaboration -- more

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors -- more

VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates -- more

BrainCells and Organon to Collaborate in Discovery and Development of CNS Drugs -- more

ExonHit to Identify a Blood Diagnostic for Atherosclerosis -- more

Cyberkinetics Enters into Definitive Agreements for $10.0 Million Private Placement -- more

Solexa Announces Sequencing of a Human X-Chromosome -- more

Critical Therapeutics Announces Acceptance of Controlled-Release Zileuton New Drug Application for Review by FDA -- more

Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG -- more

Biopharmaceutical Firm Trubion Plans 4 Million IPO Shares -- more

Technology behind Sirna Therapeutics subject of the 2006 Nobel Prize for Physiology and Medicine -- more

Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen -- more

Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model -- more

AVEO and XOMA Enter Into Supply Agreement for AVEO’s Novel Anti-HGF Antibody -- more

ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia -- more

Santhera Appoints MJ Roach as Vice President Marketing and Sales -- more

Kurt H. Kruger Joins Cyberkinetics as Chief Financial Officer -- more

ExonHit Therapeutics Extends Strategic Alliance with Allergan -- more

Santhera Appoints New Board Directors -- more

Xanthus Presents In Vitro Data Demonstrating that Symadex Is a Potent and Selective Inhibitor of FLT3 -- more

Dynogen Initiates Phase 1b Trial of DDP733 in Gastroesophageal Reflux Disease (GERD) — New Approach for Treating Nighttime Heartburn -- more

Radius & Karo Bio Announce Licensing Agreement for Novel SARM Compounds -- more

FDA Grants Humanitarian Use Device Designation to Cyberkinetics' Andara(TM) OFS Device for Acute Spinal Cord Injuries; Designation Marks Critical Regulatory Step Toward Commercialization -- more

Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin -- more

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease -- more

Exelixis Files IND Application for XL228 -- more

Solexa Appoints Blaine Bowman and Roy Whitfield to Board of Directors -- more

Critical Therapeutics Announces Results of Phase I/II Trial of Intravenous Formulation of Zileuton -- more

Sirna Therapeutics Reports Final Results from Phase 1 Study on Its RNAi-Based Therapeutic for Age-Related Macular Degeneration -- more

BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma -- more

Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists -- more

Solexa Appoints Joseph Whitters to Board of Directors -- more

Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA -- more

Memory Pharmaceuticals Achieves Milestone Under Nicotinic Alpha-7 Collaboration With Roche -- more

Cyberkinetics' Neural Sensing Technology Highlighted in Second Study Published in Nature -- more

MicroMed Announces Hiring of Alan Totah as Senior Vice President of Regulatory Affairs and Quality Systems -- more

Solexa Announces Initial System Shipments; Early Access Program Underway with Leading Genome Institutes -- more

Ceres Announces Genomics Milestone in Energy Crop Enhancement Program -- more

PowderMed to Conduct Clinical Trial of its Novel DNA-Based H5N1 (Avian) Influenza Vaccine in London -- more

Asterand signs partnership to supply drug discovery services to Japan -- more

Solexa Joins Russell 3000 Index -- more

Asterand Announces Collaboration with Rubicon Genomics to Develop New Cancer Diagnostic Tests -- more

Cyberkinetics Reports Preliminary BrainGate Data from Non-Speaking, Paralyzed Participant at ASIA Meeting in Boston -- more

Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs -- more

European Patent Office Significantly Limits Scope of Kreutzer-Limmer RNAi Patent Claim -- more

Rib-X Pharmaceuticals Raises $50 Million in Series C Financing -- more

MicroMed Announces Closing of $15.425 Million Financing -- more

Ceres and Noble Foundation Establish Collaboration for New Energy Crops -- more

Cyberkinetics Reports First Data from Non-Speaking, Paralyzed Participant in Ongoing Study of BrainGate Neural Interface System - Expanded Evidence of Brain Computer Interface Utility Presented at ASSFN Meeting in Boston -- more

Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting -- more

Xanthus Meets Milestone in Phase 2 Clinical Study of Xanafide for Treatment of Secondary AML -- more

Trubion Files for Initial Public Offering -- more

Rib-X Pharmaceuticals and Wakunaga Pharmaceutical Company Announce License Agreement for Quinolone Antibiotic -- more

Cyberkinetics and Minnetronix Finalize Design and Manufacturing Agreement for the Andara OFS Device to Treat Acute Spinal Cord Injuries -- more

UMass Medical School Partners with PowderMed to Test Potential Avian Flu Vaccine -- more

Study in the Journal "Vaccine" Reports Positive Results of DNA-Based Flu Vaccine in Humans -- more

Sirna Therapeutics Announces Pricing of Common Stock Offering -- more

Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development -- more

Solexa Added to NASDAQ Biotech Index -- more

Sirna Therapeutics Licenses Worldwide Exclusive Rights to microRNA Technology from University of Massachusetts Medical School -- more

Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline -- more

Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006 -- more

CardioFocus Completes Series C Financing; H.I.G. Ventures and KBL Healthcare Ventures Lead $21.5 Million Round for Developer of First Endoscopically-Guided Catheter Ablation System to Treat Atrial Fibrillation -- more

Asterand Announces New Test to Reduce Risks in Human Drug Trials -- more

Targacept Announces Pricing of Its Initial Public Offering -- more

Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer -- more

HydroCision receives 2006 ‘Medical Design Excellence Award’ (MDEA) for its SpineJet® MicroResector -- more

GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease -- more

PowderMed's Therapeutic DNA Vaccine for Chronic Hepatitis B Enters Phase 1 Clinical Trials in Patients -- more

ExonHit and BioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples -- more

Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes -- more

ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

Dynogen Initiates Phase II Trial of DDP225 for Treatment of Chronic Functional Vomiting -- more

Sirna Therapeutics Announces Its Scientific Advisory Board -- more

X-Cell Begins Trial of its Ethos DES Product Using Estradiol -- more

X-Cell Medical Initiates Enrollment for ETHOS II Clinical Trial of Estradiol Eluting Stent -- more

R. Scott Greer Named Chairman of the Board of Sirna Therapeutics and Lutz Lingnau Appointed as New Board Member -- more

Inverness Medical Innovations Acquires CLONDIAG Chip Technologies -- more

Memory Pharmaceuticals Expands Roche Nicotinic Alpha-7 Alliance -- more

X-Cell Medical: Putting Safety First -- more

Solexa Transfers Listing to The Nasdaq National Market -- more

ExonHit Therapeutics Will Begin Continuous Trading on Alternext -- more

Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton -- more

ExonHit SpliceArray Service Welcomes Its 50th Commercial Contract -- more

Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors -- more

Astex grants Cytochrome P450 license to Pfizer -- more

Solexa Completes Second Closing of $65 Million Private Equity Financing -- more

Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia -- more

Targacept Files for Initial Public Offering -- more

Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer -- more

Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in Cancer Patients -- more

AVEO Pharmaceuticals Acquires Rights to Novel Anti-Cancer Compound from Mitsubishi Pharma Corporation -- more

Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals -- more

Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business -- more

Xanthus Initiates Phase 2 Clinical Trial with Symadex in Women With Metastatic Breast Cancer -- more

Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement -- more

Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors -- more

Inverness Medical Innovations Receives FDA Clearance for Sale of its Albumin Cobalt Binding (ACB(R)) Test for Detection of Ischemia Modified Albumin (IMA(R)) on Roche Chemistry Analyzers -- more

Exelixis and Wyeth Sign License Agreement Related to Novel Treatments for Metabolic and Liver Diseases -- more

Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program -- more

Critical Therapeutics Initiates Pharmacokinetic Studies of Zileuton Controlled-Release Tablets; Data to support New Drug Application for twice-a-day formulation of zileuton -- more

Santhera Raises CHF 25 million (€16 million) Via a Further Closing of its 2005 B Financing Round -- more

Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd. -- more

Memory Pharmaceuticals Announces Agreement with the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder -- more

Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients -- more

Exelixis Initiates Phase II Clinical Program for XL999 -- more

Critical Therapeutics to Initiate Clinical Study of Intravenous Formulation of Zileuton; Phase I/II Asthma Study Scheduled to Begin in the First Quarter of 2006 -- more

Santhera Starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedrich's Ataxia -- more

Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 -- more

Solexa Introduces the Solexa Genome Analysis System -- more

Critical Therapeutics Achieves Collaboration Milestone in HMGB1 Program; Demonstrates Efficacy of HMGB1 Antibodies in Preclinical Models of Inflammation -- more

Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Novel Cardiovascular Disease Treatments -- more

Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs -- more

NBC's Today Show Features Cyberkinetics' BrainGate System: In Clinical Trials to 'Turn Thought into Action'; Clinical Trial Participant with Quadriplegia Uses His Own Thoughts to Control a Computer and a Prosthetic Hand -- more

New Paper Highlights ExonHit's Novel Approach for the Treatment of Alzheimer's Disease -- more

X-Cell Medical Completes Enrollment for Clinical Trial of ETHOS I Estradiol Eluting Stent -- more

Solexa Announces Agreement for $65 Million Private Placement -- more

Sirna Therapeutics to Join the NASDAQ Biotechnology Index -- more

Xanthus Life Sciences Appoints J. Kris Piper as Vice President of Regulatory Affairs and Quality Assurance -- more

BioProcessors: Having Identified Rapid, Early Process Development as Critical to the Success of Novo Nordisk’s Biologics Programs, Company Chooses SimCell® MicroBioreactor System For High-Throughput Mammalian Cell Culture Process Development -- more

Elixir: Want to Live Forever? -- more

FlowMedica Inc., Completes $15 Million Series D Financing -- more

Critical Therapeutics' Study Suggests Steroid-Sparing Effect of ZYFLO(R) in Patients with Severe Asthma -- more

Memory Pharmaceuticals Commences Phase 2a Trial of MEM 1003 in Alzheimer's Disease -- more

Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich’s Ataxia -- more

Critical Therapeutics' ZYFLO(R) Reduces Need for Rescue Medication and Significantly Improves Lung Function in Severe Asthma Patients -- more

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction -- more

Cardiome Acquires Artesian Therapeutics -- more

Xanthus Initiates a Phase 2 Study Of Xanafide in Combination with ara-C for Treatment Of Secondary AML -- more

Santhera Targets New Indication with its Lead Compound -- more

BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer -- more

Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen -- more

Dynogen Initates Phase II Trial of DDP225 for Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome -- more

Cellzome and Santhera's business unit, Graffinity, awarded Euro 2.2 million grant from German Government -- more

Critical Therapeutics Announces Commercial Launch of ZYFLO(R); Studies Showed ZYFLO Reduced the Need for Rescue Medications and Improved Asthma Symptoms -- more

John P. Donoghue Honored for Cyberkinetics' Groundbreaking BrainGate(TM) Brain-Computer Interface at the 'Popular Mechanics 2005 Breakthrough Awards -- more

Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for the Treatment of Cancer -- more

Avalon Pharmaceuticals Announces Pricing of Initial Public Offering -- more

Xanthus Life Sciences Awarded Grant from NCI to Develop Technology for Personalized Dosing of Anticancer Drugs -- more

Sirna Therapeutics and Allergan Enter Into Strategic Ophthalmology Alliance -- more

Critical Therapeutics Announces FDA Approval of ZYFLO(R) for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms -- more

Dynogen initiates Phase II trial of DDP733 for treatment of patients with constipation-predominant irritable bowel syndrome -- more

Cyberkinetics Announces $11.4 Million Private Financing -- more

Memory Pharmaceuticals Completes Safety and Tolerability Study of MEM 1003; Preparing to Commence Dosing Patients in Phase 2a Trial -- more

Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer -- more

Memory Pharmaceuticals Announces $31 Million Financing -- more

Merger of Pharmagene Plc and Asterand, Inc. to Form a Leading Company in Human Tissue Supply and Human Tissue Based Research Services -- more

Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program -- more

ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors -- more

Avalon Pharmaceuticals, Inc. Announces Filing of IND for AVN944 for the Treatment of Cancer -- more

Solexa and Collaborating Scientists Illuminate the Small RNA Component of the Transcriptome; Research Published in ''Science'' Demonstrates the Value of High-Throughput Sequencing in Small RNA Analysis -- more

Astex announces new drug discovery collaboration with Boehringer Ingelheim -- more

Cardiome Announces LOI to Acquire Artesian Therapeutics -- more

Dennis H. Langer Appointed to Sirna Therapeutics Board of Directors -- more

ALS Patients Offered Access to Cyberkinetics' BrainGate(TM) System in New Pilot Study at Massachusetts General Hospital -- more

World Renowned Geneticist David Bentley, D.Phil., Joins Solexa as Chief Scientist -- more

X-Cell Medical Commences Randomized Clinical Trial of Estradiol Eluting Stent -- more

Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases -- more

Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease -- more

PowderMed Manufactures a Vaccine Against HSN1 (Avian Influenza) for Clinical Development -- more

AstraZeneca and Astex announce new anti-cancer drug discovery alliance -- more

BioSource Signs Definitive Merger Agreement and Reports Record Second Quarter Sales -- more

Exelixis Initiates Phase I Clinical Trial for Anticancer Compound XL820 -- more

First Demonstration of Systemic siRNA Efficacy at Therapeutically Relevant Doses is Published by Sirna Therapeutics -- more

BrainCells Inc. Announces $17.7 Million Series A Financing -- more

BioProcessors’ SimCell™ Platform Demonstrates Potential to Increase Amgen’s Cell Culture Experiment Capacity -- more

Solexa Completes $24 Million Private Equity Financing -- more

Sirna Therapeutics Completes Initial Closing of a $28 Million Financing -- more

Elixir Pharmaceuticals: Nature Publication Reports Key Links Between Mechanisms of Aging and Metabolic Disorders -- more

James B. Tananbaum, M.D. Joins Critical Therapeutics' Board of Directors -- more

Cambrios Names Xina Quan as First Vice President of Research & Development -- more

US Tissue Bank, Asterand, Expands Service to Europe -- more

Astex Announces IND Approval for Novel Cancer Drug AT7519 -- more

ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

Critical Therapeutics Announces Closing of $54.5 Million Private Placement -- more

MedImmune And Avalon Pharmaceuticals Announce Collaboration to Discover Small Molecule Therapeutic Drugs for Inflammatory Diseases -- more

Exelixis Files IND Application for Anticancer Compound XL184 -- more

Sirna Therapeutics Announces Collaboration with Massachusetts General Hospital to Evaluate Potential of siRNAs in Hearing Restoration -- more

Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 and XL784 -- more